Advertisement

Impact of age on toxicity and efficacy of 5-FU-based combination chemotherapy among patients with metastatic colorectal cancer; a pooled analysis of five randomized trials

  • Omar Abdel-RahmanEmail author
  • Hatim Karachiwala
Original Article
  • 31 Downloads

Abstract

Objective

To assess the impact of age on toxicity and efficacy outcomes of metastatic colorectal cancer treated with 5FU-based combination chemotherapy.

Methods

Project Data Sphere (PDS) platform has been accessed and de-identified datasets of the following clinical trials were downloaded (NCT00272051; NCT00305188; NCT00115765; NCT00364013; and NCT00384176). Multivariable logistic regression analysis was used to assess the impact of age (< 70 years versus ≥ 70 years) on the probability of different toxicities. Multivariable Cox regression analysis was additionally used to evaluate the impact of age (< 70 years versus ≥ 70 years) on overall and progression-free survival.

Results

Among a total of 3223 patients included in the current analysis, 2488 patients were < 70 years; while 735 patients were ≥ 75 years at randomization. Older age was associated with a higher probability of serious adverse events (OR (odds ratio) 0.649; 95% CI 0.545–0.772; P < 0.001), fatal adverse events (OR 0.416; 95% CI 0.299–0.579; P < 0.001), all-grade diarrhea (OR 0.834; 95% CI 0.699–0.994, P = 0.043), high-grade diarrhea (OR 0.734; 95% CI 0.577–0.933, P = 0.012), high-grade stomatitis (OR 0.500, 95% CI 0.290–0.861, P = 0.012), high-grade thrombocytopenia (OR 0.578; 95% CI 0.359–0.930, P = 0.024), all-grade neutropenia (OR 0.690; 95% CI 0.578–0.824, P < 0.001), and high-grade neutropenia (OR 0.661; 95% CI 0.549–0.796, P < 0.001). In a multivariable Cox regression analysis for factors affecting overall survival, older age was associated with worse overall survival (hazard ratio for younger age versus older age 0.848; 95% CI 0.754–0.954, P = 0.006). On the hand, older age was not associated with worse progression-free survival (hazard ratio for younger age versus older age 0.933; 95% CI 0.843–1.032, P = 0.179).

Conclusion

Metastatic colorectal cancer patients ≥ 70 years of age who are treated with 5FU-based combination chemotherapy are more likely to have serious adverse events, fatal adverse events as well as worse overall survival compared to younger patients.

Keywords

Age Prognosis Colon cancer Rectal cancer Outcomes 

Notes

Acknowledgments

This publication is based on research using information obtained from www.projectdatasphere.org, which is maintained by the Project Data Sphere, LLC. Neither Project Data Sphere, LLC nor the owner(s) of any information from the website have contributed to, approved, or are in any way responsible for the contents of this publication.

Compliance with ethical standards

Ethical approval

All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all participants included in the study.

References

  1. 1.
    Kim JH (2015) Chemotherapy for colorectal cancer in the elderly. World J Gastroenterol 21(17):5158–5166CrossRefGoogle Scholar
  2. 2.
    Millan M, Merino S, Caro A, Feliu F, Escuder J, Francesch T (2015) Treatment of colorectal cancer in the elderly. World J Gastrointest Oncol 7(10):204–220CrossRefGoogle Scholar
  3. 3.
    Grande R, Natoli C, Ciancola F, Gemma D, Pellegrino A, Pavese I et al (2016) Treatment of metastatic colorectal cancer patients ≥75 years old in clinical practice: a multicenter analysis. PLoS One 11(7):e0157751-eCrossRefGoogle Scholar
  4. 4.
    Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14(11):1077–1085CrossRefGoogle Scholar
  5. 5.
    Orum M, Gregersen M, Jensen K, Meldgaard P, Damsgaard EMS (2018) Frailty status but not age predicts complications in elderly cancer patients: a follow-up study. Acta Oncol 57(11):1458–1466CrossRefGoogle Scholar
  6. 6.
  7. 7.
    Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Tian Y, Xu F, Sidhu R (2014) Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25(7):1346–1355CrossRefGoogle Scholar
  8. 8.
    Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27(5):672–680CrossRefGoogle Scholar
  9. 9.
    Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, van Cutsem E (2012) Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 30(29):3588–3595CrossRefGoogle Scholar
  10. 10.
    Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386–1422CrossRefGoogle Scholar
  11. 11.
    Nitsche U, Stöss C, Friess H (2017) Effect of adjuvant chemotherapy on elderly colorectal cancer patients: lack of evidence. Gastrointest Tumors 4(1–2):11–19CrossRefGoogle Scholar
  12. 12.
    Saad AM, Abdel-Rahman O (2019) Initial systemic chemotherapeutic and targeted therapy strategies for the treatment of colorectal cancer patients with liver metastases. Expert Opin Pharmacother.  https://doi.org/10.1080/14656566.2019.1642324
  13. 13.
    Landre T, Uzzan B, Nicolas P, Aparicio T, Zelek L, Mary F, Taleb C, Des Guetz G (2015) Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. A meta-analysis. Int J Color Dis 30(10):1305–1310CrossRefGoogle Scholar
  14. 14.
    Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FLG, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJL, van Bochove A, Sinnige HAM, Creemers GJM, Tesselaar MET, Slee PHTJ, Werter MJBP, Mol L, Dalesio O, Punt CJA (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370(9582):135–142CrossRefGoogle Scholar
  15. 15.
    Abdel-Rahman O (2019) Impact of sex on chemotherapy toxicity and efficacy among patients with metastatic colorectal cancer: pooled analysis of 5 randomized trials. Clin Colorectal Cancer 18(2):110–5.e2CrossRefGoogle Scholar
  16. 16.
    Abdel-Rahman O (2019) Outcomes of non-metastatic colon cancer patients in relationship to socioeconomic status: an analysis of SEER census tract-level socioeconomic database. Int J Clin Oncol.  https://doi.org/10.1007/s10147-019-01497-9
  17. 17.
    Abdel-Rahman O (2018) Challenging a dogma: five-year survival does not equal cure in all colorectal cancer patients. Expert Rev Anticancer Ther 18(2):187–192CrossRefGoogle Scholar
  18. 18.
    Abdel-Rahman O (2019) 5-fluorouracil-related cardiotoxicity; findings from five randomized studies of 5-fluorouracil-based regimens in metastatic colorectal cancer. Clin Colorectal Cancer 18(1):58–63CrossRefGoogle Scholar
  19. 19.
    Abdel-Rahman O, Ahmed O (2019) Predictors of toxicity-related hospitalization in four randomized studies of 5-fluorouracil-based chemotherapy in metastatic colorectal cancer. Int J Color Dis 34(4):675–680CrossRefGoogle Scholar
  20. 20.
    Abdel-Rahman O (2019) Prognostic value of baseline ALBI score among patients with colorectal liver metastases: a pooled analysis of two randomized trials. Clin Colorectal Cancer 18(1):e61–ee8CrossRefGoogle Scholar
  21. 21.
    Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J (2016) Inclusion of elderly patients in oncology clinical trials. Ann Oncol 27(9):1799–1804CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Oncology, Cross Cancer InstituteUniversity of AlbertaEdmontonCanada

Personalised recommendations